A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis
The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).
Helping patients is the greatest motivation for the research team at Orion. Even the smallest successes inspire the researcher to work harder.
"I’m inspired by our input in research and product development. For example, great opportunities may be presented by biologic drugs, which are being developed extensively around the world", says Christer Nordstedt.
"The tasks of a doctor in the pharmaceutical industry are versatile and educational", says Kristiina Kuismanen.
“If you manage to develop even one good cancer drug that is effective and well tolerated, it will have an earth-shattering global impact. This is a goal that is worth working towards,” says Joensuu.